Berend Olivier studied biology at the University of Groningen, The Netherlands, and obtained his Ph.D. degree in 1977. Ensuing, he joined the pharmaceutical company Solvay-Duphar in Weesp, The Netherlands, where he developed a new class of psychotropic drugs, serenics, for the clinical treatment of psychiatric patients with pathological destructive (aggressive) behavior. As the Head of the CNS Pharmacology Department, he was responsible for drug discovery of antidepressants, antipsychotics, anxiolytics, and serenics and led the research and discovery of the SSRI fluvoxamine which is marketed as an antidepressant and anti-OCD drug. Several new drugs were found and developed including flesinoxan (a 5-HT1A receptor agonist-clinical phase III), cilansetron (a 5-HT3 receptor antagonist for IBS in phase 3), DU 125530 (a 5-HT1A receptor antagonist in Phase II), and various other drugs in earlier development stages. Since 1992, Olivier is a Professor of CNS pharmacology, Utrecht University. He spent two years (1999-2000) as a VP Research of a start-up biotech company, PsychoGenics Inc., near New York ,and since 1991, he has been a Full Professor and the Chairman of the Department of Psychopharmacology at the Faculty of Pharmaceutical Sciences. He is also an Adjunct Professor at Yale University School of Medicine at the Department of Psychiatry. He leads an active research program in Utrecht using animal models of anxiety, depression, impulsivity, and sexual behavior to study the mechanism of action of psychoactive drugs. Since August 2008, Olivier is the Scientific Director of the Utrecht Institute for Pharmaceutical Sciences.
Biography Updated on 21 June 2009